Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02634216 · ClinicalTrials.gov registry record · NA
Effects of Capros in Patients With Type-1 Diabetes
A NA study of Type I Diabetes, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT02634216: Completed NA study of Type I Diabetes, sponsored by Ohio State University.
NCT02634216 is a NA study of Type I Diabetes that has completed, run by Ohio State University. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02634216, a NA study of Type I Diabetes, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this 12 week longitudinal study is to test the effect of the dietary supplement, Capros, on blood glycemic index of Type 1 diabetics that have a sensor that provides continuous glucose monitoring (CGM). 20 Type 1 Diabetics will take the Capros supplement for 12 weeks to determine the effect of blood glycemic index. Capros, is a generally safe dietary supplement currently sold over the counter in the United States. Type 1 diabetes also known as juvenile diabetes is commonly diagnosed in children and young adults. Insulin is converted into energy needed for daily living, and with diabetes, insulin is not produced in the body as it should causing many problems. In traditional Indian medicine, the gooseberry Phyllanthus emblica has been used for thousands of years as an effective source of polyphenols and antioxidants. A 12 week longitudinal study to determine the effect of the dietary supplement, Capros, on the blood glycemic index in patients with Type 1 diabetes (T1D).
Primary Outcome
To determine the effect on blood glycemic index in Type 1 Diabetics with taking the nutritional supplement Capros
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Capros
Study Locations (3)
Ohio
- Carepoint East 543 Taylor Ave. - Columbus
- Martha Morehouse Medical Plaza 2050 Kenny Road - Columbus
- Davis Heart and Lung Research Institute - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-05-25 |
| Phase | NA |
What the finished NCT02634216 record still lists
NCT02634216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Type I Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Capros is the first listed.
NCT02634216 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02634216 about?
NCT02634216 is a clinical study titled "Effects of Capros in Patients With Type-1 Diabetes". The purpose of this 12 week longitudinal study is to test the effect of the dietary supplement, Capros, on blood glycemic index of Type 1 diabetics that have a sensor that provides continuous glucose monitoring (CGM). 20 Type 1 Diabetics will take the Capros supplement for 12 weeks to determine the ...
What is the current status of trial NCT02634216?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2016-05-25.
What conditions does trial NCT02634216 study?
This clinical trial studies the following conditions: Type I Diabetes.
What interventions are being tested in trial NCT02634216?
The interventions under investigation include: Capros (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02634216?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02634216 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02634216's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia